Haleon Accelerates Revenue Growth and Launches $2 Billion Debt Refinancing

Key Facts

1Haleon reported 2.6% organic revenue growth for H1 2026, with growth accelerating to 3.1% in Q2.

2RBC Capital raised its price target for Haleon’s London-listed shares from 370 pence to 390 pence.

3Haleon launched a tender offer for approximately $2 billion of notes due in March 2027 as part of a debt-refinancing strategy.

In a move reflecting a strategic focus on profitability and balance sheet optimization, Haleon reported positive financial results for the first half of 2026. The company achieved organic revenue growth of 2.6% during H1, with performance accelerating to 3.1% in the second quarter. These results stem from the company's ongoing efforts to drive productivity gains and sustainable operational growth within the consumer healthcare sector.

Alongside business growth, Haleon launched a tender offer to repurchase approximately $2 billion of notes due in March 2027, a step aimed at refinancing near-term obligations and optimizing the company's debt profile. Per market data, analysts reacted positively to these maneuvers, with RBC Capital raising its price target for the London-listed shares from 370 pence to 390 pence while maintaining a Sector Perform rating.

At the close on August 10, 2026, HLN.L in London stood at 365.2 pence, while the NYSE-listed HLN closed at $9.93 and GSK at $52.16. Investors should monitor the progress of the debt tender offer and its impact on liquidity levels, as global markets continue to digest broader economic data such as the recently released US ISM Services PMI which printed at 54.1.

Sources:

Financial Modeling Prep